Year All202420232022202120202019 Sep 24, 2024 Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer Sep 19, 2024 Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH Sep 18, 2024 Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024 Sep 13, 2024 Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 15, 2024 Aligos Therapeutics Announces Reverse Stock Split Aug 08, 2024 Aligos Therapeutics Strengthens Board with Two New Independent Directors Aug 06, 2024 Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results Jul 30, 2024 Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024 Jul 22, 2024 Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd. Jul 10, 2024 Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB
Sep 24, 2024 Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
Sep 19, 2024 Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
Sep 18, 2024 Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
Aug 06, 2024 Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results
Jul 22, 2024 Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.
Jul 10, 2024 Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB
